Related references
Note: Only part of the references are listed.Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification
Carla Montironi et al.
GUT (2023)
Conceptual Model for the Hepatocellular Carcinoma Screening Continuum: Current Status and Research Agenda
Amit G. Singal et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)
Association between ultrasound quality and test performance for HCC surveillance in patients with cirrhosis: a retrospective cohort study
Nicolas Chong et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)
Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression
Lorenzo A. Orci et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)
Nonalcoholic steatohepatitis (NASH) cirrhosis: a snapshot of therapeutic agents in clinical development and the optimal design for clinical trials
Pankaj Aggarwal et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2022)
T cells: Friends and foes in NASH pathogenesis and hepatocarcinogenesis
Pierluigi Ramadori et al.
HEPATOLOGY (2022)
Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease
Jennifer R. Kramer et al.
HEPATOLOGY (2022)
Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study
Shukui Qin et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis
Amit G. Singal et al.
JOURNAL OF HEPATOLOGY (2022)
Treatment Candidacy for Pharmacologic Therapies for NASH
Ian A. Rowe et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Thomas Yau et al.
LANCET ONCOLOGY (2022)
Immunotherapies for hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
Advancing the global public health agenda for NAFLD: a consensus statement
Jeffrey Lazarus et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2022)
T cell immunity against liver cancer in mice
John C. McVey et al.
ISCIENCE (2022)
Dynamic Changes in Ultrasound Quality for Hepatocellular Carcinoma Screening in Patients With Cirrhosis
Haley Schoenberger et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)
CXCR2 inhibition enables NASH-HCC immunotherapy
Jack Leslie et al.
GUT (2022)
NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options
Friedrich Foerster et al.
JOURNAL OF HEPATOLOGY (2022)
Metformin treatment rescues CD8+T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD
Simon Wabitsch et al.
JOURNAL OF HEPATOLOGY (2022)
Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis
Darren Jun Hao Tan et al.
LANCET ONCOLOGY (2022)
Rifaximin Ameliorates Non-alcoholic Steatohepatitis in Mice Through Regulating gut Microbiome-Related Bile Acids
Jie Jian et al.
FRONTIERS IN PHARMACOLOGY (2022)
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : a multicentre, open-label, randomised, phase 3 trial
Robin Kate Kelley et al.
LANCET ONCOLOGY (2022)
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
Andrew X. Zhu et al.
NATURE MEDICINE (2022)
Hepatocellular carcinoma
Arndt Vogel et al.
LANCET (2022)
Molecular pathogenesis and systemic therapies for hepatocellular carcinoma
Josep M. Llovet et al.
NATURE CANCER (2022)
Immune cell-mediated features of non-alcoholic steatohepatitis
Thierry Huby et al.
NATURE REVIEWS IMMUNOLOGY (2022)
Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma
Frank Juhling et al.
GUT (2021)
Use of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta-Analysis
Erin Wolf et al.
HEPATOLOGY (2021)
Steatohepatitis Impairs T-cell-Directed Immunotherapies Against Liver Tumors in Mice
Bernd Heinrich et al.
GASTROENTEROLOGY (2021)
rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis
Kevin Teo et al.
JOURNAL OF HEPATOLOGY (2021)
Maladaptive regeneration - the reawakening of developmental pathways in NASH and fibrosis
Changyu Zhu et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Daniel Q. Huang et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)
Hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS DISEASE PRIMERS (2021)
Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial
Etienne Garin et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)
Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease
Ramy Younes et al.
JOURNAL OF HEPATOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Convergent somatic mutations in metabolism genes in chronic liver disease
Stanley W. K. Ng et al.
NATURE (2021)
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
Arun J. Sanyal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Therapeutic pipeline in nonalcoholic steatohepatitis
Raj Vuppalanchi et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)
Associations Among Adipose Tissue Immunology, Inflammation, Exosomes and Insulin Sensitivity in People With Obesity and Nonalcoholic Fatty Liver Disease
Anja Fuchs et al.
GASTROENTEROLOGY (2021)
Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study
Riad Salem et al.
HEPATOLOGY (2021)
Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis
Roser Pinyol et al.
JOURNAL OF HEPATOLOGY (2021)
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores
Cristiana Bianco et al.
JOURNAL OF HEPATOLOGY (2021)
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister et al.
NATURE (2021)
Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH
Michael Dudek et al.
NATURE (2021)
Association of Obesity With Survival Outcomes in Patients With Cancer A Systematic Review and Meta-analysis
Fausto Petrelli et al.
JAMA NETWORK OPEN (2021)
Sinusoidal endotheliopathy in nonalcoholic steatohepatitis: therapeutic implications
Samar H. Ibrahim
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2021)
Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020)
Philipp K. Haber et al.
GASTROENTEROLOGY (2021)
Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma.
Philipp K. Haber et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Epidemiology and risk-stratification of NAFLD-associated HCC
George N. Ioannou
JOURNAL OF HEPATOLOGY (2021)
Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention
Naomi F. Lange et al.
JOURNAL OF HEPATOLOGY (2021)
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study
Zhenggang Ren et al.
LANCET ONCOLOGY (2021)
XCR1+ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis
Aleksandra Deczkowska et al.
NATURE MEDICINE (2021)
Hepatocellular Carcinoma - Origins and Outcomes
Robin K. Kelley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Outcomes after curative therapy for hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: a meta-analysis and review of current literature
Ken M. Chin et al.
HPB (2021)
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
Tim F. Greten et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister et al.
NATURE (2021)
Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease
Ju Dong Yang et al.
HEPATOLOGY (2020)
Bariatric surgery is associated with reduction in non-alcoholic steatohepatitis and hepatocellular carcinoma: A propensity matched analysis
Minyoung Kwak et al.
AMERICAN JOURNAL OF SURGERY (2020)
Liver transplant for hepatocellular carcinoma in the United States: Evolving trends over the last three decades
Marc Puigvehi et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2020)
Transarterial Chemoembolization of Hepatocellular Carcinoma: Propensity Score Matching Study Comparing Survival and Complications in Patients with Nonalcoholic Steatohepatitis Versus Other Causes Cirrhosis
Shamar Young et al.
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY (2020)
Adaptive immunity: an emerging player in the progression of NAFLD
Salvatore Sutti et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: Expert Review
Rohit Loomba et al.
GASTROENTEROLOGY (2020)
Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes
Yamini Natarajan et al.
HEPATOLOGY (2020)
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Fibrosis and cancer: A strained relationship
Bram Piersma et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2020)
Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort
Quentin M. Anstee et al.
JOURNAL OF HEPATOLOGY (2020)
Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders
Judith Aron-Wisnewsky et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality
Tracey G. Simon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
Bruno Sangro et al.
JOURNAL OF HEPATOLOGY (2020)
Senolytic CAR T cells reverse senescence-associated pathologies
Corina Amor et al.
NATURE (2020)
Hepatitis C-Related Hepatocellular Carcinoma Incidence in the Veterans Health Administration After Introduction of Direct-Acting Antivirals
Lauren A. Beste et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
The genomic landscape of Mongolian hepatocellular carcinoma
Julian Candia et al.
NATURE COMMUNICATIONS (2020)
Can You Trust Your Gut? Implicating a Disrupted Intestinal Microbiome in the Progression of NAFLD/NASH
Kavita Jadhav et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
Loss of hepatocyte cell division leads to liver inflammation and fibrosis
Matthew R. Dewhurst et al.
PLOS GENETICS (2020)
Pathogenesis of Nonalcoholic Steatohepatitis: An Overview
Gopanandan Parthasarathy et al.
HEPATOLOGY COMMUNICATIONS (2020)
Inadequate Hepatocellular Carcinoma Screening in Patients With Nonalcoholic Steatohepatitis Cirrhosis
Elizabeth Aby et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2019)
Angiopoietin-2 Promotes Pathological Angiogenesis and Is a Therapeutic Target in Murine Nonalcoholic Fatty Liver Disease
Sander Lefere et al.
HEPATOLOGY (2019)
High incidence of hepatocellular carcinoma and postoperative complications in patients with nonalcoholic steatohepatitis as a primary indication for deceased liver transplantation
Barbara Kern et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2019)
Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts
Myriam Alexander et al.
BMC MEDICINE (2019)
Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study
Debashis Haldar et al.
JOURNAL OF HEPATOLOGY (2019)
Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification
George N. Ioannou et al.
JOURNAL OF HEPATOLOGY (2019)
Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer
Mohsen Malehmir et al.
NATURE MEDICINE (2019)
From NASH to HCC: current concepts and future challenges
Quentin M. Anstee et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis
Soumik BasuRay et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
NAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 Radioembolization
Clemens Schotten et al.
LIVER CANCER (2019)
Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study
Samer Gawrieh et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development
Juliette Mouries et al.
JOURNAL OF HEPATOLOGY (2019)
Performance of Hong Kong Liver Cancer staging system in patients of hepatocellular carcinoma treated with surgical resection: An Indian validation study
Shraddha Patkar et al.
JOURNAL OF SURGICAL ONCOLOGY (2019)
Landscape of Intercellular Crosstalk in Healthy and NASH Liver Revealed by Single-Cell Secretome Gene Analysis
Xuelian Xiong et al.
MOLECULAR CELL (2019)
Distribution of Coronary Flow Capacity Is Different Among the Groups by Abnormal CFR/HMR in Nonobstructive Coronary Artery Disease Patients
Jin-Sin Koh et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Resolving the fibrotic niche of human liver cirrhosis at single-cell level
P. Ramachandran et al.
NATURE (2019)
The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids
Sebastian Prill et al.
SCIENTIFIC REPORTS (2019)
Mechanisms of Immune Tolerance in Liver Transplantation-Crosstalk Between Alloreactive T Cells and Liver Cells With Therapeutic Prospects
Hong Lei et al.
FRONTIERS IN IMMUNOLOGY (2019)
Preclinical Models for Studying NASH-Driven HCC: How Useful Are They?
Mark A. Febbraio et al.
CELL METABOLISM (2019)
Association between physical activity and risk of hepatobiliary cancers: A multinational cohort study
Sebastian E. Baumeister et al.
JOURNAL OF HEPATOLOGY (2019)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2019)
The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Konstantin Kazankov et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Naga Chalasani et al.
HEPATOLOGY (2018)
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
Chris Estes et al.
HEPATOLOGY (2018)
The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017Part 2: Management and special groups
Shiv Chitturi et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2018)
Editorial: NAFLD-related hepatocellular carcinoma - increasing or not? With or without cirrhosis?
M. Balakrishnan et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis
Kristina Tzartzeva et al.
GASTROENTEROLOGY (2018)
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
Jorge A. Marrero et al.
HEPATOLOGY (2018)
Lipotoxicity and the gut-liver axis in NASH pathogenesis
Fabio Marra et al.
JOURNAL OF HEPATOLOGY (2018)
Pharmacotherapy for NASH: Current and emerging
Monica A. Konerman et al.
JOURNAL OF HEPATOLOGY (2018)
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030
Chris Estes et al.
JOURNAL OF HEPATOLOGY (2018)
A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer
Takuma Tsuchida et al.
JOURNAL OF HEPATOLOGY (2018)
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle et al.
JOURNAL OF HEPATOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Mechanisms of NAFLD development and therapeutic strategies
Scott L. Friedman et al.
NATURE MEDICINE (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells
Chi Ma et al.
SCIENCE (2018)
Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4+ T cell apoptosis promoting HCC development
Zachary J. Brown et al.
CELL DEATH & DISEASE (2018)
Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases
Jonathan G. Stine et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Molecular therapies and precision medicine for hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease
Fasiha Kanwal et al.
GASTROENTEROLOGY (2018)
Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis
Changyu Zhu et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Dietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling
Jessie Qiaoyi Liang et al.
NATURE COMMUNICATIONS (2018)
The impact of antiviral therapy on hepatocellular carcinoma epidemiology
Massimo Colombo et al.
HEPATIC ONCOLOGY (2018)
Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents
Fasiha Kanwal et al.
GASTROENTEROLOGY (2017)
The PNPLA3 Variant Associated With Fatty Liver Disease (I148M) Accumulates on Lipid Droplets by Evading Ubiquitylation
Soumik BasuRay et al.
HEPATOLOGY (2017)
Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet
Ayae Ikawa-Yoshida et al.
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity
Shabnam Shalapour et al.
NATURE (2017)
Inflammation, metaflammation and immunometabolic disorders
Gokhan S. Hotamisligil
NATURE (2017)
MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals
Benedetta Donati et al.
SCIENTIFIC REPORTS (2017)
Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease
C. R. Wong et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Neutrophil depletion improves diet-induced non-alcoholic fatty liver disease in mice
Rongying Ou et al.
ENDOCRINE (2017)
Metabolic Inflammation-Associated IL-17A Causes Non-alcoholic Steatohepatitis and Hepatocellular Carcinoma
Ana L. Gomes et al.
CANCER CELL (2016)
Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans Is Associated With Nonalcoholic Fatty Liver Disease
Sahil Mittal et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma
Riad Salem et al.
GASTROENTEROLOGY (2016)
The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent
Rosellina Margherita Mancina et al.
GASTROENTEROLOGY (2016)
Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes
Zobair M. Younossi et al.
HEPATOLOGY (2016)
The Severity of Nonalcoholic Fatty Liver Disease Is Associated With Gut Dysbiosis and Shift in the Metabolic Function of the Gut Microbiota
Jerome Boursier et al.
HEPATOLOGY (2016)
Clinical Patterns of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease: A Multicenter Prospective Study
Fabio Piscaglia et al.
HEPATOLOGY (2016)
Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma
Daniel R. Wahl et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer
Amon Asgharpour et al.
JOURNAL OF HEPATOLOGY (2016)
NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis
Chi Ma et al.
NATURE (2016)
Classification and characterization of microsatellite instability across 18 cancer types
Ronald J. Hanse et al.
NATURE MEDICINE (2016)
Clinical Presentation, Risk Factors, and Treatment Modalities of Hepatocellular Carcinoma: A Single Tertiary Care Center Experience
Abdulrahman A. Aljumah et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2016)
Temporal Trends of Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma in the Veteran Affairs Population
Sahil Mittal et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease
Venkatanarayana Gangarapu et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2015)
Genetic Landscape and Biomarkers of Hepatocellular Carcinoma
Jessica Zucman-Rossi et al.
GASTROENTEROLOGY (2015)
Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy
George V. Papatheodoridis et al.
JOURNAL OF HEPATOLOGY (2015)
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2015)
Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study
Joong-Won Park et al.
LIVER INTERNATIONAL (2015)
Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota
Kristoffer Forslund et al.
NATURE (2015)
Impact of Steatosis on Prognosis of Patients with Early-Stage Hepatocellular Carcinoma After Hepatic Resection
Chien-Wei Su et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
Effect of Metformin on Metabolic Improvement and Gut Microbiota
Heetae Lee et al.
APPLIED AND ENVIRONMENTAL MICROBIOLOGY (2014)
ER Stress Cooperates with Hypernutrition to Trigger TNF-Dependent Spontaneous HCC Development
Hayato Nakagawa et al.
CANCER CELL (2014)
Metabolic Activation of lntrahepatic CD8+ T Cells and NKT Cells Causes Nonalcoholic Steatohepatitis and Liver Cancer via Cross-Talk with Hepatocytes
Monika Julia Wolf et al.
CANCER CELL (2014)
Improved survival outcomes in patients with non-alcoholic steatohepatitis and alcoholic liver disease following liver transplantation: an analysis of 2002-2012 United Network for Organ Sharing data
Robert J. Wong et al.
CLINICAL TRANSPLANTATION (2014)
Continuation of Metformin Use After a Diagnosis of Cirrhosis Significantly Improves Survival of Patients With Diabetes
Xiaodan Zhang et al.
HEPATOLOGY (2014)
Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene
Hwa-Li Tan et al.
JOURNAL OF GASTROENTEROLOGY (2014)
Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team
Jessica Dyson et al.
JOURNAL OF HEPATOLOGY (2014)
Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma
Y. -L. Liu et al.
JOURNAL OF HEPATOLOGY (2014)
Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease
Julia Kozlitina et al.
NATURE GENETICS (2014)
Prognostic Significance of AMPK Activation and Therapeutic Effects of Metformin in Hepatocellular Carcinoma
Longyi Zheng et al.
CLINICAL CANCER RESEARCH (2013)
Statins Are Associated With a Reduced Risk of Hepatocellular Cancer: A Systematic Review and Meta-analysis
Siddharth Singh et al.
GASTROENTEROLOGY (2013)
Characterization of Gut Microbiomes in Nonalcoholic Steatohepatitis (NASH) Patients: A Connection Between Endogenous Alcohol and NASH
Lixin Zhu et al.
HEPATOLOGY (2013)
Role of Vascular Endothelial Growth Factor in the Pathophysiology of Nonalcoholic Steatohepatitis in Two Rodent Models
Stephanie Coulon et al.
HEPATOLOGY (2013)
Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma
Shingo Tanaka et al.
JOURNAL OF GASTROENTEROLOGY (2013)
Hepatic Stellate Cells Preferentially Induce Foxp3+ Regulatory T Cells by Production of Retinoic Acid
Richard M. Dunham et al.
JOURNAL OF IMMUNOLOGY (2013)
A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma
Masato Fujii et al.
MEDICAL MOLECULAR MORPHOLOGY (2013)
Failure Rates in the Hepatocellular Carcinoma Surveillance Process
Amit G. Singal et al.
CANCER PREVENTION RESEARCH (2012)
The DNA damage checkpoint protein ATM promotes hepatocellular apoptosis and fibrosis in a mouse model of non-alcoholic fatty liver disease
Erin K. Daugherity et al.
CELL CYCLE (2012)
Association Between Nonalcoholic Fatty Liver Disease and Risk for Hepatocellular Cancer, Based on Systematic Review
Donna L. White et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2012)
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia-Pacific trial
Ann-Lii Cheng et al.
EUROPEAN JOURNAL OF CANCER (2012)
Excess body weight and the risk of primary liver cancer: An updated meta-analysis of prospective studies
Yi Chen et al.
EUROPEAN JOURNAL OF CANCER (2012)
Fibrosis-dependent mechanisms of hepatocarcinogenesis
David Y. Zhang et al.
HEPATOLOGY (2012)
Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis
Adriaan J. van der Meer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
Jordi Bruix et al.
JOURNAL OF HEPATOLOGY (2012)
Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression
Janine Kah et al.
ONCOLOGY REPORTS (2012)
MYC Phosphorylation, Activation, and Tumorigenic Potential in Hepatocellular Carcinoma Are Regulated by HMG-CoA Reductase
Zhongwei Cao et al.
CANCER RESEARCH (2011)
Simvastatin modulates the adhesion and growth of hepatocellular carcinoma cells via decrease of integrin expression and ROCK
Borna Relja et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2011)
Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression
Eek Joong Park et al.
CELL (2010)
Randomized Controlled Trial Testing the Effects of Weight Loss on Nonalcoholic Steatohepatitis
Kittichai Promrat et al.
HEPATOLOGY (2010)
Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study
Eduardo Fassio et al.
ANNALS OF HEPATOLOGY (2010)
The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma
J. Polesel et al.
ANNALS OF ONCOLOGY (2009)
Coffee, Decaffeinated Coffee, and Tea Consumption in Relation to Incident Type 2 Diabetes Mellitus A Systematic Review With Meta-analysis
Rachel Huxley et al.
ARCHIVES OF INTERNAL MEDICINE (2009)
Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma
Yujin Hoshida et al.
CANCER RESEARCH (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma
Derek Y. Chiang et al.
CANCER RESEARCH (2008)
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4+CD25+Foxp3+ T cells
Bastian Hoechst et al.
GASTROENTEROLOGY (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth
Monica Buzzai et al.
CANCER RESEARCH (2007)
Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs
Emilie Roudier et al.
MOLECULAR CANCER THERAPEUTICS (2006)
The association between diabetes and hepatocellular carcinoma: A systematic review of epidemiologic evidence
HB El-Serag et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors.: Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor
AP Sutter et al.
JOURNAL OF HEPATOLOGY (2005)
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease
E Bugianesi et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
Coffee diterpenes prevent the genotoxic effects of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and N-nitrosodimethylamine in a human derived liver cell line (HepG2)
BJ Majer et al.
FOOD AND CHEMICAL TOXICOLOGY (2005)
Cafestol and kahweol, two coffee specific diterpenes with anticarcinogenic activity
C Cavin et al.
FOOD AND CHEMICAL TOXICOLOGY (2002)
In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases
S Seki et al.
JOURNAL OF HEPATOLOGY (2002)